NEJM STUDY FINDS RISK OF THROMBOTIC STROKE & MYOCARDIAL INFARCTION WITH HORMONAL PILLS CONTAINING EE ESTROGEN IN YAZ,YASMIN, BEYAZ & SAFYRAL PILLS
In “THROMBOTIC STROKE AND MYOCARDIAL INFARCTION WITH HORMONAL CONTRACEPTION“, an Abstract in the prestigious New England Journal of Medicine (NEJM) evaluates 15 years of data to address the risk of thrombotic stroke and heart attacks, or myocardial infarction, in birth control pills that contain ETHINYL ESTRADIOL (EE) as an estrogen. Until now, most of the focus and risks associated with the trademarked YASMIN, YAZ, BEYAZ & SAFYRAL pills centered on their containing the protesting DROSPIRENONE (DRSP). As noted in other posts, independent studies, and an FDA funded study have confirmed they present a higher risk of blood clots in comparison to other pills. This “new” study followed women from the ages of 15-49 with no prior history of heart disease or cancer. The data analyzed involved 1.6 Million women and compared certain types of available hormonal contraceptives and the risks associated with the for thrombotic strokes and heart attacks. The authors concluded that there was a link between those pills that contain .02 micrograms of ETHINYL ESTRADIOL (EE), as well as those that varied from .03 micrograms to .04 micrograms. The risk was increased by a factor of 0.9-1.7 in those with .02 micrograms and 1.3-2.3 for those with .03-.04 micrograms of ETHINYL ESTRADIOL (EE). The only difference between YASMIN & YAZ is the difference in the amount of ETHINYL ESTRADIOL, as well as the length of dosing. Similarly, the difference between BEYAZ & SAFYRAL is the addition of folate. Basically, all DROSPIRENONE (DRSP) containing birth control pills fall within either of these higher risk ranges. The point is not how low the probability of an adverse event is, but whether or not consumers are being properly warned by the manufacturer before they choose their pills.
What does this add to the risks associated with the use of a DROSPIRENONE (DRSP) containing birth control? Another factor for all prescribers, girls, their Mothers and adult women to consider when choosing their hormonal contraceptive. Why would any DROSPIRENONE (DRSP) birth control pill be the 1st choice for any 1st time user, or why would any woman switch from an established hormonal contraceptive to a DROSPIRENONE (DRSP) containing birth control pill if they are properly and adequately informed of available data and risks? Arguably, they would not.
Unfortunately, many girls, their Mothers, adult women and their prescribers did not know any better prior to 2009. Mounting evidence appears to confirm that DROSPIRENONE (DRSP) containing birth control pills present higher risks that outweigh their effectiveness and that the FDA or manufacturer should consider a market withdrawal or recall.
FREE CASE EVALAUTIONS are available through use of the contact form below from the sponsor of this site. We will evaluate and consider cases from the time that DROSPIRENONE (DRSP) containing birth controls pills, and their generic equivalents were launched until such time that they are ultimately recalled, if ever.